ClinicalTrials.gg

Gastrointestinal Stromal Tumors clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 343 studies for Gastrointestinal Stromal Tumors across more than 10 countries. 61 are recruiting or about to start. 252 of them are mainly about Gastrointestinal Stromal Tumors (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

Status

Completed
183
Recruiting
49
Status unknown
34
Terminated
31
Active, not recruiting
18
Not yet recruiting
9

Phase

Phase 2
136
Phase 1
64
Phase 3
38
Phase 4
11
Early Phase 1
2

Where

United States
139
China
69
France
48
Germany
41
Korea, Republic of
41
Italy
34

Who develops what

Add Gastrointestinal Stromal Tumors to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 6 programs from 6 companies, 5 with this as their studies’ main aim; 3 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bayer, GlaxoSmithKline and Ono Pharmaceutical here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
SunitinibRecent, repeated
Evidence
  • NCT07218926 · GlaxoSmithKline · Phase 3 · live · comparator · “Sunitinib” · registered Oct 2025
  • NCT05734105 · Ono Pharmaceutical Co. Ltd · Phase 3 · live · comparator · “Sunitinib” · registered Feb 2023
  • NCT05208047 · Cogent Biosciences, Inc. · Phase 3 · live · background · “Sunitinib” · registered Dec 2021
  • NCT04633122 · Zai Lab Limited · Phase 2 · comparator · “Sunitinib” · registered Nov 2020
  • NCT04409223 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “Sunitinib Capsules” · registered May 2020
Pfizer76% of its industry studiesUS: off-patent, 7 generics marketedEU: off-patent, 1 generic authorized33 studies

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ripretinibApproved: US 2020 · EU 2021☆ Track2 live phase-3 studies: NCT03673501, NCT05734105Ono Pharmaceutical Co. Ltd
velzatinib☆ Track2 live phase-3 studies: NCT07585266, NCT07218926GlaxoSmithKline
NB-003☆ Track1 live phase-3 study: NCT07379047Ningbo Newbay Technology Development Co., Ltd

The 3 in phase 3 with the nearest primary completion, of 6 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Oct 2027 est.SOS1 Inhibitor MRTX0902 · Kumquat Biosciences Inc. · Phase 2 main aimNCT07406633 KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line) — primary endpoint: Objective response rate (ORR) · 46 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Gastrointestinal Stromal Tumors studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 21 open · Immune checkpoint inhibitors 2 open · Angiogenesis inhibitors 1 open · Antimitotic agents 1 open · Antimetabolites 6

Coming up

20studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger. 6 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (4%) take healthy volunteers.

Recruiting studies that take each age, of 49
AgeWomenMen
105 (10%)5 (10%)
1844 (90%)44 (90%)
3048 (98%)48 (98%)
4048 (98%)48 (98%)
5048 (98%)48 (98%)
6548 (98%)48 (98%)
7548 (98%)48 (98%)
8543 (88%)43 (88%)

Across all 343 studies, recruiting or not: 10% stop at 75 or younger and 3% at 65; 13% take children; 1% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Gastrointestinal Stromal Tumors studies take

Of 47 phase 2 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 62 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 135 mo26–77 · 21 studies——
Phase 262 mo38–92 · 47 studies——
Observational70 mo44–90 · 34 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 343. Browse all 343 → or search them.